This is a phase II double-blinded, multi-site, placebo-controlled study that aims to assess the safety, efficacy & dose response characterisation of STSO1 (Dithranol/ProSilic) administered topically, once daily, to affected scalp areas for 6 months in patients who have mild to moderate Alopecia Areata.
Key Study Information:
To assess the safety, efficacy & dose response characterisation of STSO1 (Dithranol/ProSilic) administered topically, once daily, to affected scalp areas for 6 months, in patients who have mild to moderate Alopecia Areata.
100 patients with mild to moderate Alopecia
- Details of practice revenue available on request.
Speak to our study support specialist for more information on this study.
10 minutes to participate in this study
Practice - Select a study
Your practice can choose a study via our website or dedicated web application.
Practice - Review & Approve Eligible Patients
uMed searches are compatible with EMIS or SystmOne. The results of this search are available to your practice in our web application for sign-off.
uMed - Patient Contact
We provide a dedicated study support line for all patient enquiries to minimise incoming calls to your practice.
For most studies, between 10-30% of patients engage with our outreach.
Patient - Consents to Join Study
Once the study concludes, we will share results and patient feedback with you so that you can see the impact of your participation. Any revenue generated from commercial studies is shared with your practice.
Not yet registered with uMed? Join over 400 GP Practices across the UK within the uMed Research Network and take part in the ALOPECIA study. Join the uMed Research Network.
Register your interest in this study
Fill in the below form and a member of our team will be in touch to discuss next steps to participate in this study.